貨號
產(chǎn)品規格
售價(jià)
備注
BN42019M-50ul
50ul
￥1486.00
交叉反應：Rat(predicted:Mouse,Chicken,Dog,Pig,Cow,Rabbit,Sheep,GuineaPig,Monkey,Insect, Yeast) 推薦應用：WB,IHC-P,IHC-F,ICC,IF,ELISA
BN42019M-100ul
100ul
￥2360.00
交叉反應：Rat(predicted:Mouse,Chicken,Dog,Pig,Cow,Rabbit,Sheep,GuineaPig,Monkey,Insect, Yeast) 推薦應用：WB,IHC-P,IHC-F,ICC,IF,ELISA
產(chǎn)品描述
| 英文名稱(chēng) | TNF alpha |
| 中文名稱(chēng) | 腫瘤壞死因子-α單克隆抗體 |
| 別 名 | Tumor necrosis factor-α; TNFalpha; APC1; Cachectin; DIF; Differentiation inducing factor; Macrophage cytotoxic factor; MCF; Necrosin; TNF a; TNF-alpha; TNF; TNF Macrophage Derived; TNF Monocyte Derived; TNF Superfamily Member 2; TNFA; TNFSF2; Tumor necrosis factor ligand superfamily member 2; Tumor Necrosis Factor Precurso; Tumour Necrosis Factor Alpha. |
| 研究領(lǐng)域 | 細胞骨架 細胞外基質(zhì) |
| 抗體來(lái)源 | Mouse |
| 克隆類(lèi)型 | Monoclonal |
| 克 隆 號 | 3A4 |
| 交叉反應 | Rat, (predicted: Mouse, Chicken, Dog, Pig, Cow, Rabbit, Sheep, Guinea Pig, Monkey, Insect, Yeast) |
| 產(chǎn)品應用 | WB=1:1000-2000 ELISA=1:5000-10000 IHC-P=1:200-500 IHC-F=1:200-500 ICC=1:100-500 IF=1:200-500 （石蠟切片需做抗原修復） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 17/26kDa |
| 細胞定位 | 細胞膜 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Recombinant human TNF alpha 77-233aa : |
| 亞 型 | IgG1 |
| 純化方法 | affinity purified by Protein G |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | Tumor Necrosis Factor Alpha (TNF alpha) is a protein secreted by lipopolysaccharide stimulated macrophages, and causes tumor necrosis when injected into tumour bearing mice. TNF alpha is believed to mediate pathogenic shock and tissue injury associated with endotoxemia. TNF alpha exists as a multimer of two, three, or five noncovalently linked units, but shows a single 17 kDa band following SDS PAGE under non reducing conditions. TNF alpha is closely related to the 25 kDa protein Tumour Necrosis Factor beta (lymphotoxin), sharing the same receptors and cellular actions. TNF alpha causes cytolysis or cytostasis of certain transformed cells, being synergistic with interferon gamma in its cytotoxicity. Although it has little effect on many cultured normal human cells, TNF alpha appears to be directly toxic to vascular endothelial cells. Other actions of TNF alpha include stimulating growth of human fibroblasts and other cell lines, activating polymorphonuclear neutrophils and osteoclasts, and induction of interleukin 1, prostaglandin E2 and collagenase production. TNF alpha is currently being evaluated in treatment of certain cancers and AIDS Related Complex. Function: Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells. Subunit: Homotrimer. Interacts with SPPL2B.. Subcellular Location: Cell membrane; Single-pass type II membrane protein. Tumor necrosis factor, membrane form: Membrane; Single-pass type II membrane protein. Tumor necrosis factor, soluble form: Secreted. C-domain 1: Secreted. C-domain 2: Secreted. Post-translational modifications: The soluble form derives from the membrane form by proteolytic processing. The membrane-bound form is further proteolytically processed by SPPL2A or SPPL2B through regulated intramembrane proteolysis producing TNF intracellular domains (ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space. The membrane form, but not the soluble form, is phosphorylated on serine residues. Dephosphorylation of the membrane form occurs by binding to soluble TNFRSF1A/TNFR1. O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid. DISEASE: Genetic variations in TNF are a cause of susceptibility psoriatic arthritis (PSORAS) [MIM:607507]. PSORAS is an inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoidlike pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis). Similarity: Belongs to the tumor necrosis factor family. SWISS: P01375 Gene ID: 7124 Database links: Entrez Gene: 7124 Human Entrez Gene: 21926 Mouse Omim: 191160 Human SwissProt: P01375 Human SwissProt: P06804 Mouse Unigene: 241570 Human Unigene: 1293 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
在線(xiàn)咨詢(xún)
English
